Sublingual DMT + harmine creates a controllable, repeatable psychedelic session — but 'controllable' must be proven in trial data, not just claimed in slides. Videra Health captures the dose-response, session-to-session consistency, and integration patterns that turn 'novel formulation' into 'differentiated asset.'
See how we'd observe REDIReconnect Labs' sublingual DMT plus harmine program — an ayahuasca-derived formulation engineered for controllable session duration, repeatable dosing, and clinic-administered care.
REDI is sublingual DMT + harmine — an ayahuasca-derived formulation engineered for controllable session duration, repeatable dosing, and clinic-administered care. The hypothesis: capture the durable therapeutic effects associated with ayahuasca, in a format that fits modern clinical infrastructure.
Sublingual administration means clinicians can dose, monitor, and adjust without the complexity of traditional ayahuasca preparation. The session is more controllable, the experience more reproducible. In theory.
'Controllable' has to be proven, not assumed. Observable behavioral measurement during and across sessions captures the dose-response, session-to-session consistency, and integration patterns that turn 'novel formulation' into 'differentiated asset.' Standard endpoints capture symptoms. They don't capture session dynamics.
The market opportunity is built on the assumption that ayahuasca-like benefits can be productized. Proving it requires data the standard endpoint stack was not built to capture.
Building the case for productized ayahuasca-derived therapy.
Four observation gaps separate 'sublingual DMT + harmine' from 'differentiated psychedelic asset.'
Session-to-session variability in onset, peak, and integration phases is observable in vocal, facial, and somatic signal. The data that turns 'controllable' from a marketing word into a clinical finding.
Behavioral observation across dose levels surfaces the dose-response curve in a way that supports both label claims and clinical dosing guidance.
Post-session integration is where the therapeutic durability is forged. Continuous behavioral capture between sessions surfaces the integration patterns that predict outcomes.
Whether REDI delivers the durable benefits associated with ayahuasca depends on what trial data shows about session dynamics, integration, and longitudinal outcomes. Videra captures all three.
Bring us a question and we'll capture the data. Bring us your data and we'll run it through our models. Or start from a hypothesis and we'll co-develop a novel endpoint with you, end-to-end.
We bring the hardware, software, and AI to your site. Behavioral signal collected the same way at every visit, every site, every time.
Bring us your existing video, voice, or trial data. Our multimodal models surface vocal, facial, and linguistic biomarkers you couldn't see in PRO data alone.
Start from a clinical hypothesis. We build the digital endpoint, the screener, or the response model end-to-end — from study design through peer review.
Our platform pairs in-clinic AI hardware with multimodal behavioral analytics and a custom algorithm engine, already proven in TDScreen and Check on Mom. Here's how each maps to REDI.
A clinical-grade camera and directional audio rig that drops into any REDI Phase 1 site in minutes. Every session captured at the same fidelity — the baseline for proving session-to-session consistency and dose-response.
Broad, continuous observation of the full room and the patient during the REDI session. Videra algorithms run on captured video, voice, and movement signal — triggering alerts on abnormalities, acute findings, and protocol-defined events.
Multi-view cameras and high-fidelity audio focused on close-contact patient–provider interactions. Purpose-built to monitor protocol adherence remotely and protect the fidelity of the trial.
Stream Videra carts from one or many rooms to a single central observation point, scaling oversight across REDI sites — in clinic and at commercial launch.
Multimodal analysis of voice, video, and language during the sublingual session and across the integration period that follows. The data that supports the 'productized ayahuasca' commercial story.
For REDI, that means a proprietary controllability index and integration pattern model — measuring what 'controllable session' actually looks like in trial data, and predicting durability from session-level signal.
AI-powered tardive dyskinesia screening built on the AIMS standard. A short, video-based assessment that quantifies involuntary movements, reducing reliance on subjective rating. AUC 0.89 vs. trained raters, peer-reviewed in J Clin Psychiatry.
Consumer-friendly video assessment for perinatal & postpartum depression. Surfaces postpartum risk earlier than standard EPDS administration, and routes to care with rich signal.
Multimodal AI model trained on REDI Phase 1+ data, quantifying session controllability, integration depth, and durability prediction for the ayahuasca-derived commercial story.
Co-developed with your team, the same way we built TDScreen and Check on Mom for our existing pharma partners.
Your REDI development strategy, mapped to Videra capabilities in production.
Videra's network isn't our customer base. It's the living dataset that powers every algorithm we build. For Reconnect Labs, that means real clinical depth and peer-reviewed validation.
We'd welcome a 30-minute session to walk Reconnect Labs through a tailored, protocol-by-protocol proposal for REDI's clinical development plan.